Analysts Set Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) PT at $71.40

Shares of Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT) have been given a consensus rating of “Buy” by the eight analysts that are covering the company, MarketBeat Ratings reports. Seven investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $71.40.

ARCT has been the topic of a number of recent research reports. Leerink Partners initiated coverage on Arcturus Therapeutics in a research report on Monday, August 12th. They issued an “outperform” rating and a $70.00 target price on the stock. Leerink Partnrs upgraded Arcturus Therapeutics to a “strong-buy” rating in a research note on Monday, August 12th. HC Wainwright lifted their target price on Arcturus Therapeutics from $60.00 to $63.00 and gave the stock a “buy” rating in a research note on Thursday, August 8th. Finally, Cantor Fitzgerald restated an “overweight” rating on shares of Arcturus Therapeutics in a research note on Monday, September 9th.

Institutional Trading of Arcturus Therapeutics

Large investors have recently bought and sold shares of the company. Russell Investments Group Ltd. purchased a new stake in Arcturus Therapeutics in the first quarter worth $40,000. Quest Partners LLC bought a new position in shares of Arcturus Therapeutics in the fourth quarter worth $67,000. Point72 Asia Singapore Pte. Ltd. bought a new position in shares of Arcturus Therapeutics in the second quarter worth $142,000. CANADA LIFE ASSURANCE Co boosted its holdings in shares of Arcturus Therapeutics by 10.5% in the first quarter. CANADA LIFE ASSURANCE Co now owns 4,492 shares of the biotechnology company’s stock worth $152,000 after acquiring an additional 428 shares during the period. Finally, Public Employees Retirement System of Ohio boosted its holdings in shares of Arcturus Therapeutics by 63.8% in the first quarter. Public Employees Retirement System of Ohio now owns 4,620 shares of the biotechnology company’s stock worth $156,000 after acquiring an additional 1,800 shares during the period. 94.54% of the stock is owned by hedge funds and other institutional investors.

Arcturus Therapeutics Price Performance

ARCT opened at $20.61 on Monday. Arcturus Therapeutics has a one year low of $17.52 and a one year high of $45.00. The company’s 50 day simple moving average is $21.16 and its 200-day simple moving average is $27.21. The stock has a market capitalization of $555.07 million, a P/E ratio of -5.27 and a beta of 2.60.

Arcturus Therapeutics (NASDAQ:ARCT) last issued its earnings results on Monday, August 5th. The biotechnology company reported ($0.64) EPS for the quarter, beating the consensus estimate of ($1.85) by $1.21. Arcturus Therapeutics had a negative net margin of 41.21% and a negative return on equity of 25.47%. The company had revenue of $49.86 million during the quarter, compared to analysts’ expectations of $21.00 million. During the same quarter in the previous year, the company posted ($1.98) EPS. As a group, analysts anticipate that Arcturus Therapeutics will post -2.6 EPS for the current year.

Arcturus Therapeutics Company Profile

Arcturus Therapeutics Holdings Inc, a late-stage clinical messenger RNA medicines and vaccine company, focuses on the development of infectious disease vaccines and other products within liver and respiratory rare diseases. Its technology platforms include LUNAR lipid-mediated delivery and STARR mRNA.